Cariprazine in the acute treatment of unipolar and bipolar depression: A systematic review and meta-analysis.

ABSTRACT

BACKGROUND: Cariprazine has emerged as a promising augmenting treatment agent for unipolar depression and as a monotherapy option for bipolar depression. We evaluated cariprazine's efficacy in treating acute major depressive episodes in individuals with major depressive disorder (MDD) or bipolar disorder. METHODS: A systematic review was conducted on MEDLINE, Embase, PsycINFO, Scopus and Web of Science, ClinicalTrials.gov and ScanMedicine. Study quality was assessed using the RoB 2 tool. Pairwise and dose-response meta-analyses were conducted with RStudio. Evidence quality was assessed with GRADE. RESULTS: Nine RCTs meeting inclusion criteria encompassed 4889 participants. Cariprazine, compared to placebo, significantly reduced the MADRS score (MD = -1.49, 95 % CI -2.22 to -0.76) and demonstrated significantly higher response (RR = 1.21, 95 % CI 1.12 to 1.30) and remission (RR = 1.19, 95 % CI 1.06 to 1.34) rates. Subgroup analysis unveiled statistically significant reductions in MADRS score in MDD (MD = -1.15, 95 % CI -2.04 to -0.26) and bipolar I disorder (BDI) (MD = -2.53, 95 % CI -3.61 to -1.45), higher response rates for both MDD (RR = 1.19, 95 % CI 1.08 to 1.31) and BDI (RR = 1.27, 95 % CI 1.10 to 1.46), and higher remission rates only for BDI (RR = 1.41, 95 % CI 1.24 to 1.60). A higher rate of treatment discontinuation due to adverse events was observed. LIMITATIONS: Reliance solely on RCTs limits generalisability; strict criteria might not reflect real-world diversity. CONCLUSIONS: Cariprazine demonstrates efficacy in treating major depressive episodes, although variations exist between MDD and BDI and tolerability may be an issue.